Payment overview · 2025
General Payments
$702.25
27 reported records · 17 companies
Healthcare provider profile · identity verified
David Boucher, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STEPHENVILLE, TX · NPI 1639174675
Verified facts
What the public records show
CMS Open Payments records show David Boucher, MD received $702.25 in general payments during 2025 across 27 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.44 | 21.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.83 | 15.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.92 | 12.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.59 | 7.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.48 | 7.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.49 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.22 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.83 | 3.5% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $22.15 | 3.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.63 | 3.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.14 | 2.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 2.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.27 | 2.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.79 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.08 | 2.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.02 | 2.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.59 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.25 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $149.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.39 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 838 | 184 |
| Gabapentin | Gabapentin | 706 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 629 | 153 |
| Lisinopril | Lisinopril | 465 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 457 | 118 |
| Losartan Potassium | Losartan Potassium | 448 | 115 |
| Furosemide | Furosemide | 428 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 427 | 96 |
| Meloxicam | Meloxicam | 401 | 102 |
| Tramadol Hcl | Tramadol Hcl | 401 | 88 |
| Potassium Chloride | Potassium Chloride | 400 | 74 |
| Metformin Hcl | Metformin Hcl | 381 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 75 |
| Alprazolam | Alprazolam | 321 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 88 |
| Simvastatin | Simvastatin | 289 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 278 | 60 |
| Glimepiride | Glimepiride | 271 | 56 |
| Omeprazole | Omeprazole | 247 | 63 |
| Donepezil Hcl | Donepezil Hcl | 243 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 63 |
| Eliquis | Apixaban | 231 | 46 |
| Azithromycin | Azithromycin | 225 | 172 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 195 | 47 |
| Allopurinol | Allopurinol | 184 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 49 |
| Cefdinir | Cefdinir | 180 | 129 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 179 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 43 |
| Trazodone Hcl | Trazodone Hcl | 171 | 30 |
| Doxepin Hcl | Doxepin Hcl | 163 | 30 |
| Lorazepam | Lorazepam | 161 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 41 |
| Carvedilol | Carvedilol | 151 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 150 | 38 |
| Celecoxib | Celecoxib | 147 | 29 |
| Temazepam | Temazepam | 145 | 19 |
| Divalproex Sodium | Divalproex Sodium | 144 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 141 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 40 |
| Levetiracetam | Levetiracetam | 139 | 19 |
| Sertraline Hcl | Sertraline Hcl | 138 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 133 | 26 |
| Prednisone | Prednisone | 132 | 30 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 131 | 23 |
| Cephalexin | Cephalexin | 130 | 90 |
| Myrbetriq | Mirabegron | 127 | 22 |
| Finasteride | Finasteride | 121 | 28 |
| Buspirone Hcl | Buspirone Hcl | 120 | 19 |
| Ozempic | Semaglutide | 120 | 22 |
| Clonazepam | Clonazepam | 118 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 20 |
| Memantine Hcl | Memantine Hcl | 116 | 21 |
| Pregabalin | Pregabalin | 116 | 24 |
| Famotidine | Famotidine | 115 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 35 |
| Montelukast Sodium | Montelukast Sodium | 112 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 22 |
| Xarelto | Rivaroxaban | 109 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 21 |
| Methylprednisolone | Methylprednisolone | 106 | 82 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 21 |
| Atenolol | Atenolol | 88 | 17 |
| Mirtazapine | Mirtazapine | 88 | 16 |
| Alendronate Sodium | Alendronate Sodium | 84 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 53 |
| Cefuroxime | Cefuroxime Axetil | 84 | 51 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 14 |
| Aripiprazole | Aripiprazole | 81 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 23 |
| Baclofen | Baclofen | 71 | suppressed |
| Januvia | Sitagliptin Phosphate | 69 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Estradiol | Estradiol | 65 | 15 |
| Spironolactone | Spironolactone | 65 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 20 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 61 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 51 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 12 |
| Bupropion Xl | Bupropion Hcl | 56 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 24 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Risperidone | Risperidone | 51 | suppressed |
| Jardiance | Empagliflozin | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Methotrexate | Methotrexate Sodium | 48 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 26 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Digoxin | Digoxin | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 12 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Glipizide | Glipizide | 38 | 11 |
| Midodrine Hcl | Midodrine Hcl | 38 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | 12 |
| Methocarbamol | Methocarbamol | 34 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Desonide | Desonide | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $702.25 · 27 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ETERNA, FARXIGA, Fluad, Flucelvax, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, JATENZO, KEVEYIS, KRYSTEXXA, Ozempic, PREVNAR 20, TZIELD, The Cologuard Plus Collection Kit, ZENPEP, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error